Attralus Eyes Further Work on Therapeutic Candidates with New Funding

California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round. With this funding, Attralus will be able to conduct further work on its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.